S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

Registros relacionados

• S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
  por: Gili Kenet, et al.
  Publicado em: (2023-08-01)
• SAFETY AND EFFICACY OF THE FITUSIRAN REVISED ANTITHROMBIN-BASED DOSE REGIMEN IN PEOPLE WITH HAEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS (ATLAS-OLE)
  por: Guy-Young, et al.
  Publicado em: (2024-10-01)
• HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE
  por: Amy Chen, et al.
  Publicado em: (2025-11-01)
• Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B
  por: Steven W. Pipe, et al.
  Publicado em: (2025-03-01)
• HTRS2025.P1.22 Orthopedic and dental surgeries conducted under fitusiran prophylaxis in people with hemophilia A or B with or without inhibitors
  por: Larissa Bornikova, et al.
  Publicado em: (2025-11-01)